Ending the 50-year drought of FDA drug approval for SLE

Bulletin of the NYU Hospital for Joint Diseases

Volumn 69, Issue 3, 2011, Pages 238-242

  Merrill, Joan T ^a  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BELIMUMAB;

ARTICLE; B LYMPHOCYTE; CELL SURVIVAL; DROUGHT; DRUG APPROVAL; DRUG EFFICACY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERACTIVITY; LONG TERM CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES, MONOCLONAL; DRUG APPROVAL; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; STANDARD OF CARE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 80054096258     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. U.S. Food and Drug Administration: Center for Drug Evaluation and Research (Application #125370), Drug Approval Package, Medical Review of Belimumab. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist]
2. Ding C. Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases. Expert Opin Biol Ther. 2008;8:1805-14.
3. Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999;189:1747-56.
4. Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol. 2006;18:263-75.
5. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721-31.
6. Furie, R, Zamani O, Wallace D, et al. Belimumab, a BLyS-specific inhibitor, reduces disease activity and severe flares in seropositive SLE patients: bliss-76 study results through week 76. Presented at the American College of Rheumatology Annual Meeting, 2010.
7. Merrill J, Wallace DJ, Furie R, et al. Five-year experience with belimumab, a blys-specific inhibitor, in patients with systemic lupus erythematosus (SLE). Presented at the American College of Rheumatology Annual Meeting, 2010.
8. Moore E. Pitfalls of the ANA test. Available from: www.suite101.com/content/theanatesttoday-a222. Accessed September 1, 2011.
9. Williamson T. Advances in ANA testing. Available from: http://laboratory-manager.advanceweb.com/Archives/Article-Archives/Advances-in-Antinuclear-Antibody-Testing.aspx. Accessed September 1, 2011.
10. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61:1168-78
11. Merrill JT. Clinical trials for lupus-are we there yet? Bull NYU Hosp Jt Dis. 2009;67(3):267-270.
12. Isenberg DA, Allen E, Farewell V, et al. An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. Ann Rheum Dis. 2011;70(1):54-9.
13. Merrill J, Buyon J, Furie R, et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus. 2011;20(7):709-16.
14. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in patients with moderately-to-severely active systemic lupus erythematosus (SLE): Results from the randomized, double-blind phase II/III study EXPLORER Arthritis Rheum. 2010;62:222-33.
15. Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of SLE: Results of A 12-month exploratory study. Arthritis Rheum. 2010;62(10):3077-87
16. Bruce IN, Gordon C, Merrill JT, Isenberg D. Clinical trials in lupus: what have we learned so far? Rheumatology (Oxford). 2010;49(6):1025-7.
17. Merrill JT, Buyon JP. Rituximab: Wanted dead or alive Arthritis Rheum. 2010;62(8):2188-91.
18. Merrill J, Buyon J, Furie R, et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus. 2011;20(7):709-16.
19. FDA Advisory Committee Briefing Package on belimuab. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials.